Belharra Therapeutics

San Diego, United States

Belharra Therapeutics disrupts the drug discovery paradigm with its novel photoaffinity-based chemoproteomics platform.

$50.0M raised

Jan 2023

Series A

Biotechnology Chemical Therapeutics

Top Investors

Versant Ventures

Founder Contacts

30,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Belharra Therapeutics

How much funding has Belharra Therapeutics raised?

Belharra Therapeutics has raised $50.0M in total funding. The most recent round was Series A. The last funding was announced in January 2023.

Who are Belharra Therapeutics's investors?

Belharra Therapeutics's investors include Versant Ventures.

Where is Belharra Therapeutics headquartered?

Belharra Therapeutics is headquartered in San Diego, United States.

What does Belharra Therapeutics do?

Belharra Therapeutics disrupts the drug discovery paradigm with its novel photoaffinity-based chemoproteomics platform.

What stage is Belharra Therapeutics at?

Belharra Therapeutics is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 4, 2023.

MLA

"Belharra Therapeutics — Funding & Investors." VCBacked, January 4, 2023, https://www.vcbacked.co/company/belharra-therapeutics. Accessed July 2, 2026.

APA

VCBacked. (2023). Belharra Therapeutics — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/belharra-therapeutics

Wikipedia (cite web)

{{cite web |title=Belharra Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/belharra-therapeutics |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 4, 2023.